192 related articles for article (PubMed ID: 31550560)
1. Progress in targeted therapeutic drugs for oral squamous cell carcinoma.
Liu L; Chen J; Cai X; Yao Z; Huang J
Surg Oncol; 2019 Dec; 31():90-97. PubMed ID: 31550560
[TBL] [Abstract][Full Text] [Related]
2. Molecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma.
Jensen DH; Dabelsteen E; Specht L; Fiehn AM; Therkildsen MH; Jønson L; Vikesaa J; Nielsen FC; von Buchwald C
J Pathol; 2015 Aug; 236(4):505-16. PubMed ID: 25925492
[TBL] [Abstract][Full Text] [Related]
3. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
Bozec A; Peyrade F; Milano G
Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
[TBL] [Abstract][Full Text] [Related]
4. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
[TBL] [Abstract][Full Text] [Related]
5. Translational genomics and recent advances in oral squamous cell carcinoma.
Chai AWY; Lim KP; Cheong SC
Semin Cancer Biol; 2020 Apr; 61():71-83. PubMed ID: 31542510
[TBL] [Abstract][Full Text] [Related]
6. Honokiol inhibits in vitro and in vivo growth of oral squamous cell carcinoma through induction of apoptosis, cell cycle arrest and autophagy.
Huang KJ; Kuo CH; Chen SH; Lin CY; Lee YR
J Cell Mol Med; 2018 Mar; 22(3):1894-1908. PubMed ID: 29363886
[TBL] [Abstract][Full Text] [Related]
7. EZH2-mediated upregulation of ROS1 oncogene promotes oral cancer metastasis.
Shih CH; Chang YJ; Huang WC; Jang TH; Kung HJ; Wang WC; Yang MH; Lin MC; Huang SF; Chou SW; Chang E; Chiu H; Shieh TY; Chen YJ; Wang LH; Chen L
Oncogene; 2017 Nov; 36(47):6542-6554. PubMed ID: 28759046
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-induced programmed cell death ligand-2 expression is associated with metastasis ability in oral squamous cell carcinoma.
Sudo S; Kajiya H; Okano S; Sasaki M; Katsumata Y; Ohno J; Ikebe T; Hiraki A; Okabe K
Cancer Sci; 2020 Apr; 111(4):1113-1123. PubMed ID: 32012401
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of targeting cell division cycle associated 5 for oral squamous cell carcinoma.
Tokuzen N; Nakashiro K; Tanaka H; Iwamoto K; Hamakawa H
Oncotarget; 2016 Jan; 7(3):2343-53. PubMed ID: 26497678
[TBL] [Abstract][Full Text] [Related]
10. Targeting the non-canonical AKT-FOXO3a axis: A potential therapeutic strategy for oral squamous cell carcinoma.
Liu Y
EBioMedicine; 2019 Nov; 49():6-8. PubMed ID: 31648985
[No Abstract] [Full Text] [Related]
11. IFIT1 and IFIT3 promote oral squamous cell carcinoma metastasis and contribute to the anti-tumor effect of gefitinib via enhancing p-EGFR recycling.
Pidugu VK; Wu MM; Yen AH; Pidugu HB; Chang KW; Liu CJ; Lee TC
Oncogene; 2019 Apr; 38(17):3232-3247. PubMed ID: 30626937
[TBL] [Abstract][Full Text] [Related]
12. The role of E-cadherin down-regulation in oral cancer: CDH1 gene expression and epigenetic blockage.
Pannone G; Santoro A; Feola A; Bufo P; Papagerakis P; Lo Muzio L; Staibano S; Ionna F; Longo F; Franco R; Aquino G; Contaldo M; De Maria S; Serpico R; De Rosa A; Rubini C; Papagerakis S; Giovane A; Tombolini V; Giordano A; Caraglia M; Di Domenico M
Curr Cancer Drug Targets; 2014; 14(2):115-27. PubMed ID: 24274398
[TBL] [Abstract][Full Text] [Related]
13. HH/GLI signalling as a new therapeutic target for patients with oral squamous cell carcinoma.
Yan M; Wang L; Zuo H; Zhang Z; Chen W; Mao L; Zhang P
Oral Oncol; 2011 Jun; 47(6):504-9. PubMed ID: 21536478
[TBL] [Abstract][Full Text] [Related]
14. miR-654-5p Targets GRAP to Promote Proliferation, Metastasis, and Chemoresistance of Oral Squamous Cell Carcinoma Through Ras/MAPK Signaling.
Lu M; Wang C; Chen W; Mao C; Wang J
DNA Cell Biol; 2018 Apr; 37(4):381-388. PubMed ID: 29364705
[TBL] [Abstract][Full Text] [Related]
15. Telomeric repeat-binding factor 2: a marker for survival and anti-EGFR efficacy in oral carcinoma.
Benhamou Y; Picco V; Raybaud H; Sudaka A; Chamorey E; Brolih S; Monteverde M; Merlano M; Lo Nigro C; Ambrosetti D; Pagès G
Oncotarget; 2016 Jul; 7(28):44236-44251. PubMed ID: 27329590
[TBL] [Abstract][Full Text] [Related]
16. Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma.
Maruse Y; Kawano S; Jinno T; Matsubara R; Goto Y; Kaneko N; Sakamoto T; Hashiguchi Y; Moriyama M; Toyoshima T; Kitamura R; Tanaka H; Oobu K; Kiyoshima T; Nakamura S
Int J Oral Maxillofac Surg; 2018 Jul; 47(7):836-845. PubMed ID: 29395669
[TBL] [Abstract][Full Text] [Related]
17. Genetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapies.
Fadlullah MZ; Chiang IK; Dionne KR; Yee PS; Gan CP; Sam KK; Tiong KH; Ng AK; Martin D; Lim KP; Kallarakkal TG; Mustafa WM; Lau SH; Abraham MT; Zain RB; Rahman ZA; Molinolo A; Patel V; Gutkind JS; Tan AC; Cheong SC
Oncotarget; 2016 May; 7(19):27802-18. PubMed ID: 27050151
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor effect of the mammalian target of rapamycin inhibitor everolimus in oral squamous cell carcinoma.
Naruse T; Yanamoto S; Yamada S; Rokutanda S; Kawakita A; Kawasaki G; Umeda M
Pathol Oncol Res; 2015 Jul; 21(3):765-73. PubMed ID: 25682238
[TBL] [Abstract][Full Text] [Related]
19. Stathmin guides personalized therapy in oral squamous cell carcinoma.
Ju WT; Ma HL; Zhao TC; Liang SY; Zhu DW; Wang LZ; Li J; Zhang ZY; Zhou G; Zhong LP
Cancer Sci; 2020 Apr; 111(4):1303-1313. PubMed ID: 31994271
[TBL] [Abstract][Full Text] [Related]
20. Personalized Targeted Therapeutic Strategies against Oral Squamous Cell Carcinoma. An Evidence-Based Review of Literature.
Cao M; Shi E; Wang H; Mao L; Wu Q; Li X; Liang Y; Yang X; Wang Y; Li C
Int J Nanomedicine; 2022; 17():4293-4306. PubMed ID: 36134201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
